Researchers in Delft University of Technology’s Kavli Institute of Nanoscience in The Netherlands have cast new light on the workings of the important cancer inhibitor topotecan. Little had been known about the underlying molecular mechanism, but the Delft scientists can now view the effects of the medicine live at the levelin of a single DNA molecule. The research is being published this week in the journal Nature. The lead author of the article, Daniel Koster, will receive his PhD at TU Delft on Monday June 25, partly on the results described in the article.
